Craig Suvanevej's questions to Corvus Pharmaceuticals Inc (CRVS) leadership • Q2 2025
Question
Sam, on behalf of Craig Suvanevej from Mizuho Securities, asked for an update on the enrollment progress for the socolitinib trial in Peripheral T-cell Lymphoma (PTCL) and sought confirmation on the previously guided timeline for interim data.
Answer
CEO Richard Miller confirmed that the PTCL trial enrollment is proceeding as planned, with approximately 20 centers now active in the U.S. and Canada. He reiterated that the company's guidance for releasing interim data in late 2026 remains intact.